METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets liver fat in MASH patients
Disease control Recruiting nowThis early-stage study tests whether the drug miricorilant can lower the amount of fat the liver produces in people with MASH, a serious fatty liver condition. Eight adults with MASH will take the drug for 6 weeks, and researchers will measure changes in liver fat production and …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:25 UTC
-
New Genetic-Targeting drug hopes to tackle fatty liver disease
Disease control Recruiting nowThis early-stage study tests an experimental drug called ALN-PNP in healthy adults and people with a type of fatty liver disease (MASLD) who have a specific gene variant. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Vitamin B3 shows promise in battle against fatty liver disease
Disease control Recruiting nowThis study tests whether a low dose of niacin (vitamin B3), taken after meals, can help reduce fat buildup in the liver of people with metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The go…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated May 20, 2026 11:53 UTC